96 related articles for article (PubMed ID: 19551499)
1. Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.
Freedman O; Amir E; Dranitsaris G; Napolskikh J; Kumar R; Fralick M; Chia S; Petrella T; Dent S; Tonkin K; Ahmad I; Rayson D; Clemons M
Breast Cancer Res Treat; 2009 Nov; 118(2):377-83. PubMed ID: 19551499
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
3. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
Cheung KL; Owers R; Robertson JF
Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
[TBL] [Abstract][Full Text] [Related]
7. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Neven P; Paridaens R; Pelgrims G; Martens M; Bols A; Goeminne JC; Vindevoghel A; Demol J; Stragier B; De Greve J; Fontaine C; Van Den Weyngaert D; Becquart D; Borms M; Cocquyt V; Van Den Broecke R; Selleslags J; Awada A; Dirix L; Van Dam P; Azerad MA; Vandenhoven G; Christiaens MR; Vergote I
Breast Cancer Res Treat; 2008 May; 109(1):59-65. PubMed ID: 17592772
[TBL] [Abstract][Full Text] [Related]
10. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
[TBL] [Abstract][Full Text] [Related]
11. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
Abram P; Maass N; Rea D; Simon SD; Steger GG
Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
[TBL] [Abstract][Full Text] [Related]
12. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
Mahtani RL; Stein A; Vogel CL
Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC
Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005
[TBL] [Abstract][Full Text] [Related]
14. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
[TBL] [Abstract][Full Text] [Related]
15. Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment.
Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Mader RM; Gnant M; Jakesz R; Rudas M; Zielinski CC; Steger GG
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4435-9. PubMed ID: 17671127
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
18. Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer.
Litsas G
Clin J Oncol Nurs; 2011 Dec; 15(6):674-81. PubMed ID: 22119979
[TBL] [Abstract][Full Text] [Related]
19. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
Bartsch R; Mlineritsch B; Gnant M; Niernberger T; Pluschnig U; Greil R; Wenzel C; Sevelda P; Thaler J; Rudas M; Pober M; Zielinski CC; Steger GG;
Breast Cancer Res Treat; 2009 May; 115(2):373-80. PubMed ID: 18661231
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
